Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
| Autor: | Orkin, C., Porteiro, N., Berhe, M., Dretler, R., Viciana, P., Tseng, Y., Oprea, C., Johnson, M., Kulagin, V., Man, C., Sievers, J., Currie, A., Underwood, M., Tenorio, A., Pappa, K., Wynne, B., Aboud, M., Smith, K., Gartland, M., Steinhart, C., Gatell, J. |
|---|---|
| Zdroj: | In Journal of Infection and Public Health January-February 2019 12(1):147-147 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|